Development of Novel Fluticasone/Salmeterol/Tiotropium-Loaded Dry Powder Inhaler and Bioequivalence Assessment to Commercial Products in Rats
<b>Background</b>/<b>Objectives</b>: Inhaler devices have been developed for the effective delivery of inhaled medications used in the treatment of pulmonary diseases. However, differing operating procedures across the devices can lead to user errors and reduce treatment effi...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/17/1/103 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587717632851968 |
|---|---|
| author | Hyukjun Cho Hyunji Lee Duhyeong Hwang |
| author_facet | Hyukjun Cho Hyunji Lee Duhyeong Hwang |
| author_sort | Hyukjun Cho |
| collection | DOAJ |
| description | <b>Background</b>/<b>Objectives</b>: Inhaler devices have been developed for the effective delivery of inhaled medications used in the treatment of pulmonary diseases. However, differing operating procedures across the devices can lead to user errors and reduce treatment efficacy, especially when patients use multiple devices simultaneously. To address this, we developed a novel dry powder inhaler (DPI), combining fluticasone propionate (FP), salmeterol xinafoate (SX), and tiotropium bromide (TB) into a single device designed for bioequivalent delivery compared to existing commercial products in an animal model. <b>Methods</b>: The micronized FP/SX/TB-loaded capsule was prepared by sieving, blending, and filling capsules. Capsule suitability of the drugs was investigated from the comparison of the stability of drugs within various capsule formulations to that of commercial products. The particle size of the drugs was adjusted using spiral air jet milling, and the ratio of lactose hydrate carriers was optimized by comparing the aerodynamic particle size distribution (APSD) with that of commercial products. To investigate the bioequivalence of micronized FP/SX/TB-loaded DPI to commercial products, the dissolution profile of FP/SX/TB particles and pharmacokinetics in rats were evaluated and compared to commercial products. <b>Results</b>: Capsules with hydroxypropyl methylcellulose (HPMC) without a gelling agent showed superior stability of the drugs compared to commercial products. The deposition pattern was influenced by the particle size of the drugs, and fine particle mass exhibited a significant correlation with the amount of fine carrier. Micronized FP/SX/TB-loaded DPI gave a similar APSD and dissolution profile compared to the commercial products and showed dose uniformity by the DPI device. Furthermore, micronized FP/SX/TB-loaded DPI exhibited bioequivalence to commercial products, as evidenced by no significant differences in pharmacokinetic parameters following intratracheal administration in rats. <b>Conclusions</b>: A novel triple-combination DPI containing FP/SX/TB was successfully developed, demonstrating comparable pharmacological performance to commercial products. Optimized FP/SX/TB-loaded DPI with HPMC capsule achieved bioequivalence in rat studies, suggesting its potential for improved patient compliance and therapeutic outcomes. This novel single-device DPI offers a promising alternative for triple therapy in pulmonary diseases. |
| format | Article |
| id | doaj-art-79ca16568a3e4457b6150e0db693ee69 |
| institution | Kabale University |
| issn | 1999-4923 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj-art-79ca16568a3e4457b6150e0db693ee692025-01-24T13:45:58ZengMDPI AGPharmaceutics1999-49232025-01-0117110310.3390/pharmaceutics17010103Development of Novel Fluticasone/Salmeterol/Tiotropium-Loaded Dry Powder Inhaler and Bioequivalence Assessment to Commercial Products in RatsHyukjun Cho0Hyunji Lee1Duhyeong Hwang2College of Pharmacy, Keimyung University, Daegu 42601, Republic of KoreaCollege of Pharmacy, Kyungsung University, Busan 48434, Republic of KoreaCollege of Pharmacy, Keimyung University, Daegu 42601, Republic of Korea<b>Background</b>/<b>Objectives</b>: Inhaler devices have been developed for the effective delivery of inhaled medications used in the treatment of pulmonary diseases. However, differing operating procedures across the devices can lead to user errors and reduce treatment efficacy, especially when patients use multiple devices simultaneously. To address this, we developed a novel dry powder inhaler (DPI), combining fluticasone propionate (FP), salmeterol xinafoate (SX), and tiotropium bromide (TB) into a single device designed for bioequivalent delivery compared to existing commercial products in an animal model. <b>Methods</b>: The micronized FP/SX/TB-loaded capsule was prepared by sieving, blending, and filling capsules. Capsule suitability of the drugs was investigated from the comparison of the stability of drugs within various capsule formulations to that of commercial products. The particle size of the drugs was adjusted using spiral air jet milling, and the ratio of lactose hydrate carriers was optimized by comparing the aerodynamic particle size distribution (APSD) with that of commercial products. To investigate the bioequivalence of micronized FP/SX/TB-loaded DPI to commercial products, the dissolution profile of FP/SX/TB particles and pharmacokinetics in rats were evaluated and compared to commercial products. <b>Results</b>: Capsules with hydroxypropyl methylcellulose (HPMC) without a gelling agent showed superior stability of the drugs compared to commercial products. The deposition pattern was influenced by the particle size of the drugs, and fine particle mass exhibited a significant correlation with the amount of fine carrier. Micronized FP/SX/TB-loaded DPI gave a similar APSD and dissolution profile compared to the commercial products and showed dose uniformity by the DPI device. Furthermore, micronized FP/SX/TB-loaded DPI exhibited bioequivalence to commercial products, as evidenced by no significant differences in pharmacokinetic parameters following intratracheal administration in rats. <b>Conclusions</b>: A novel triple-combination DPI containing FP/SX/TB was successfully developed, demonstrating comparable pharmacological performance to commercial products. Optimized FP/SX/TB-loaded DPI with HPMC capsule achieved bioequivalence in rat studies, suggesting its potential for improved patient compliance and therapeutic outcomes. This novel single-device DPI offers a promising alternative for triple therapy in pulmonary diseases.https://www.mdpi.com/1999-4923/17/1/103fluticasonesalmeteroltiotropiumdry powder inhaleraerodynamic particle size distributiondissolution |
| spellingShingle | Hyukjun Cho Hyunji Lee Duhyeong Hwang Development of Novel Fluticasone/Salmeterol/Tiotropium-Loaded Dry Powder Inhaler and Bioequivalence Assessment to Commercial Products in Rats Pharmaceutics fluticasone salmeterol tiotropium dry powder inhaler aerodynamic particle size distribution dissolution |
| title | Development of Novel Fluticasone/Salmeterol/Tiotropium-Loaded Dry Powder Inhaler and Bioequivalence Assessment to Commercial Products in Rats |
| title_full | Development of Novel Fluticasone/Salmeterol/Tiotropium-Loaded Dry Powder Inhaler and Bioequivalence Assessment to Commercial Products in Rats |
| title_fullStr | Development of Novel Fluticasone/Salmeterol/Tiotropium-Loaded Dry Powder Inhaler and Bioequivalence Assessment to Commercial Products in Rats |
| title_full_unstemmed | Development of Novel Fluticasone/Salmeterol/Tiotropium-Loaded Dry Powder Inhaler and Bioequivalence Assessment to Commercial Products in Rats |
| title_short | Development of Novel Fluticasone/Salmeterol/Tiotropium-Loaded Dry Powder Inhaler and Bioequivalence Assessment to Commercial Products in Rats |
| title_sort | development of novel fluticasone salmeterol tiotropium loaded dry powder inhaler and bioequivalence assessment to commercial products in rats |
| topic | fluticasone salmeterol tiotropium dry powder inhaler aerodynamic particle size distribution dissolution |
| url | https://www.mdpi.com/1999-4923/17/1/103 |
| work_keys_str_mv | AT hyukjuncho developmentofnovelfluticasonesalmeteroltiotropiumloadeddrypowderinhalerandbioequivalenceassessmenttocommercialproductsinrats AT hyunjilee developmentofnovelfluticasonesalmeteroltiotropiumloadeddrypowderinhalerandbioequivalenceassessmenttocommercialproductsinrats AT duhyeonghwang developmentofnovelfluticasonesalmeteroltiotropiumloadeddrypowderinhalerandbioequivalenceassessmenttocommercialproductsinrats |